VBI VBI Vaccines Inc.(ナスダック株コード:VBIV)(VBI)は免疫学的に推進された生物製薬会社であり、強力な疾病予防と治療に取り組んでいる。同社は今日、既存の融資者K 2 He...
ログインすると全部閲覧できます。
ログイン
VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million with its existing lender, K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.
Under the terms of the agreement, $50 million is immediately available to VBI upon closing, comprised of $30 million to refinance the outstanding facility the Company held with K2HV, and an incremental $20 million of non-dilutive funding. Future tranches of up to $25 million are committed and will be made available to VBI upon the...
VBI VBI Vaccines Inc.(ナスダック株コード:VBIV)(VBI)は免疫学的に推進された生物製薬会社であり、強力な疾病予防と治療に取り組んでいる。同社は今日、既存の融資者K 2 He...
ブラウザの共有ボタンを使って、このページを友人と共有することができます。